Avenzo Therapeutics Strengthens Executive Leadership With Appointments of Annie Chang and Aaron Hasnain Avenzo Therapeutics, Inc., a clinical-stage biotechnology company focused on developing next-generation oncology therapies, has expanded its executive leadership team with the appointments of Annie Chang as senior…
Cresco Labs Files Proxy Materials for October Shareholder Meeting as It Advances U.S. Exchange Listing Plans Cresco Labs Inc. has filed its Management Information Circular and related proxy materials ahead of its annual general and special meeting of shareholders, scheduled…
Exobiosphere and Voyager Expand ISS Missions as Demand for Microgravity Drug Discovery Rises Voyager Technologies (NYSE: VOYG) and Exobiosphere have announced two additional research campaigns aboard the International Space Station (ISS), further expanding their collaboration to provide commercial biotechnology and…
Cellares and Seoul National University Hospital Partner to Automate Manufacturing of Gene-Modified HSPC Therapy for PNH Cellares, an Integrated Development and Manufacturing Organization (IDMO), and Seoul National University Hospital (SNUH), a leading translational medical center in South Korea, have announced…
GreenMan Vision Study Finds Virtual Reality May Improve Cataract IOL Education and Patient Satisfaction GreenMan Vision, Inc. has announced the publication of a peer-reviewed, multi-center study evaluating InSightVR, a patient-specific virtual reality (VR) platform designed to help people undergoing cataract…
Therapy Gains Ground as a Go-To Solution for Everyday Stress and Social Connection Modern Health, a global workplace mental health platform, has released new international research examining how employees use therapy and other forms of mental health support. The survey…
Alkermes Reports Positive Phase 1 Results for Investigational Orexin 2 Receptor Agonist ALKS 7290 in Adult ADHD Alkermes plc (Nasdaq: ALKS) has announced positive topline results from a Phase 1 proof-of-concept study evaluating ALKS 7290, a novel investigational orexin 2…
Bristol Myers Squibb Reports Two-Year Data Showing Durable Sotyktu Efficacy in Psoriatic Arthritis Bristol Myers Squibb (NYSE: BMY) announced positive two-year results from the Phase 3 POETYK PsA-2 study and its open-label extension (OLE), providing additional evidence of durable efficacy…
IMPACT Therapeutics’ Senaparib Receives Positive EMA CHMP Opinion for Ovarian Cancer Maintenance Treatment IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on developing targeted anti-cancer therapies based on synthetic lethality mechanisms, and global specialty pharmaceutical company Pharmanovia have announced a…
Largest Lung Cancer MRD Study Demonstrates Signatera™’s Strong Prognostic Value Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, has announced new clinical data presented at the IASLC 2026 World Conference on Lung Cancer (WCLC)…
PAHO-Gilead HIV Prevention Deal in Latin America Welcomed by AHF as Civil Society Victory AIDS Healthcare Foundation (AHF), one of the world’s largest HIV/AIDS healthcare organizations, has welcomed a new agreement between Gilead Sciences and the Pan American Health Organization…
NImmune Biopharma to Present Clinical and Preclinical Data on NIM-1324 at ACG 2026, Highlighting LANCL2 Potential in Difficult-to-Treat IBD NImmune Biopharma, a private, late-stage precision inflammation and immunology (I&I) biopharmaceutical company, is set to present two studies at the American…